SOPHiA GENETICS S.A. (SOPH)
$
3.49
-0.26 (-7.45%)
Key metrics
Financial statements
Free cash flow per share
-0.6829
Market cap
233.2 Million
Price to sales ratio
3.4722
Debt to equity
0.3519
Current ratio
3.1112
Income quality
0.6198
Average inventory
5.5 Million
ROE
-0.6347
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
SOPHiA GENETICS SA operates as a healthcare technology company, specializing in advanced data analysis and insight generation through its SOPHiA DDM platform. This cloud-based software-as-a-service solution facilitates the processing of multimodal data sets and diagnostic modalities, making it valuable for hospitals, laboratories, and biopharmaceutical firms across the globe. The operating income ratio is -1.02 indicating the company's operational profitability margin. Meanwhile, the operating expenses amount to $110,505,000.00 encompassing various operational costs incurred by the organization. To maintain its capital structure, the company incurred an interest expense of $1,913,000.00 reflecting its debt servicing obligations. In terms of earnings performance, the diluted EPS is -$0.95 accounting for potential share dilution, while the EBITDA is -$51,487,000.00 a key indicator of the company's operational profitability. Established in 2011, SOPHiA GENETICS SA is headquartered in Saint-Sulpice, Switzerland, and has since emerged as a pivotal entity in the healthcare technology arena. With a market capitalization of $233,240,539.00 the company is classified as a small-cap player, reflecting its growing presence in the market. It operates in the Medical - Healthcare Information Services industry, contributing significantly to the overall market landscape and positioning itself as a key player dedicated to innovation and progress. The stock is affordable at $3.49 making it suitable for budget-conscious investors looking to enter the market. However, it is worth noting that the stock has a low average trading volume of 78,931.00 indicating lower market activity, which may suggest a need for investors to be cautious about liquidity when considering their investment. Belonging to the Healthcare sector, SOPHiA GENETICS SA is driving innovation and growth, reinforcing its commitment to advancing healthcare technology solutions that enhance data-driven decision-making in the medical field.
Is SOPHiA GENETICS S.A. (SOPH) a good investment?
Investing in SOPHiA GENETICS S.A. (SOPH) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is SOPHiA GENETICS S.A. (SOPH)'s stock forecast?
Analysts predict SOPHiA GENETICS S.A. stock to fluctuate between $2.58 (low) and $4.92 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is SOPHiA GENETICS S.A.'s market capitalization?
As of 2025-07-11, SOPHiA GENETICS S.A.'s market cap is $233,240,539, based on 66,831,100 outstanding shares.
How does SOPHiA GENETICS S.A. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, SOPHiA GENETICS S.A. has a Lower Market-Cap, indicating a difference in performance.
How can I buy SOPHiA GENETICS S.A. (SOPH) stock?
To buy SOPHiA GENETICS S.A. (SOPH) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SOPH. Place an order (Market, Limit, etc.).
What is the best time to invest in SOPHiA GENETICS S.A.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did SOPHiA GENETICS S.A. perform in the last earnings report?
Revenue: $65,173,000 | EPS: -$0.95 | Growth: -22.13%.
Where can I find SOPHiA GENETICS S.A.'s investor relations reports?
Visit https://www.sophiagenetics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for SOPHiA GENETICS S.A.?
You can explore historical data from here
What is the all-time high and low for SOPHiA GENETICS S.A. stock?
All-time high: $19.80 (2021-08-31) | All-time low: $1.69 (2022-11-09).
What are the key trends affecting SOPHiA GENETICS S.A. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
SOPHiA GENETICS SA. (NASDAQ:SOPH ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - President George Cardoza - Chief Financial Officer Conference Call Participants William Bonello - Craig-Hallum Conor McNamara - RBC Capital Markets Subbu Nambi - Guggenheim Operator Good morning, ladies and gentlemen, and welcome to the SOPHiA GENETICS Q1 2025 Earnings Call.
zacks.com
SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.21 per share a year ago.
prnewswire.com
BOSTON and ROLLE, Switzerland , May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basis Gross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectively IFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign exchange P&L impact of $5.2 million), and adjusted EBITDA loss improved 24% year-over-year to $9.8 million The company reiterates full-year guidance of revenue between $72 million and $76 million and adjusted EBITDA loss between $35 million and $39 million "We started the year strong with year-over-year revenue growth of 13%, or 15% on a constant currency basis, as the large amount of new business signed in 2024 begins to ramp," said Jurgi Camblong, PhD.
seekingalpha.com
SOPHiA GENETICS SA (NASDAQ:SOPH ) Q4 2024 Earnings Call March 4, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - President George Cardoza - Chief Financial Officer Conference Call Participants Subbu Nambi - Guggenheim Mark Massaro - BTIG Tejas Savant - Morgan Stanley Bill Bonello - Craig-Hallum Operator Good morning. My name is Liway and I'll be your conference operator today.
zacks.com
SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.37 per share a year ago.
prnewswire.com
BOSTON and ROLLE, Switzerland , March 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Revenue was $17.7 million, up 4% year-over-year or 6% on a constant currency basis excluding COVID-19-related revenue Gross margin was 68.2% on a reported basis and 74.2% on an adjusted basis, compared to 69.8% and 73.4% in the prior year period, respectively Operating loss was $17.4 million on a reported basis and $10.2 million on an adjusted basis, representing year-over-year improvements of 8% and 23%, respectively Full Year 2024 Financial Highlights Revenue was $65.2 million, up 4% year-over-year or 5% on a constant currency basis excluding COVID-19-related revenue Gross margin was 67.4% on a reported basis and 72.8% on an adjusted basis, compared to 68.8% and 72.2% in the prior year period, respectively Operating loss was $66.6 million on a reported basis and $44.8 million on an adjusted basis, representing year-over-year improvements of 11% and 20%, respectively "We continued driving widespread adoption of SOPHiA DDM™ in 2024, achieving a record number of analyses, major new customers wins, and healthy volume growth during the year, despite BioPharma headwinds which impacted overall performance and resulted in softer revenue growth than we would have liked," said Jurgi Camblong, PhD.
prnewswire.com
SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a pioneer in AI healthcare technology and a leader in data-driven medicine, announced a new milestone in the global adoption of its groundbreaking cancer testing applications MSK-ACCESS® powered with SOPHiA DDM™ and MSK-IMPACT® powered with SOPHiA DDM™. Thirty-seven prominent institutions, including top researchers and key opinion leaders worldwide, have already adopted the recently launched Liquid Biopsy and Solid Tumor applications.
prnewswire.com
BOSTON and ROLLE, Switzerland , Feb. 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full year 2024 before U.S. markets open on Tuesday, March 4, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.
See all news
